Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999

Antiviral Research

Volumn 75, Issue 3, 2007, Pages 219-226

  Bauer, Katja ^a   Schrader, Christina ^b   Suess, Jochen ^c   Wutzler, Peter ^a   Schmidtke, Michaela ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^c FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

Genotyping; Neuraminidase inhibitors; Oseltamivir; Phenotyping; Porcine influenza; Resistance; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; VIRUS HEMAGGLUTININ; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; GERMANY; GLYCOSYLATION; INFLUENZA VIRUS A H3N2; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SWINE; VIRUS ISOLATION;

AMANTADINE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GERMANY; HEMAGGLUTINATION, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; NEURAMINIDASE; OSELTAMIVIR; SWINE; ZANAMIVIR;

AVES; INFLUENZA A VIRUS; SUIDAE; SUS;

EID: 34250303103     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.03.007     Document Type: Article

References (43)

1. Abe Y., Takashita E., Sugawara K., Matsuzaki Y., Muraki Y., and Hongo S. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J. Virol. 78 (2004) 9605-9611
2. Abed Y., Bourgault A.M., Fenton R.J., Morley P.J., Gower D., Owens I.J., Tisdale M., and Boivin G. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J. Infect. Dis. 186 (2002) 1074-1080
3. Bantia S., Ghate A.A., Ananth S.L., Babu Y.S., Air G.M., and Walsh G.M. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob. Agents Chemother. 42 (1998) 801-807
4. Blick T.J., Sahasrabudhe A., McDonald M., Owens I.J., Morley P.J., Fenton R.J., and McKimm-Breschkin J.L. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 246 (1998) 95-103
5. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., and Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
6. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 (2006) 891-894
7. Buxton R.C., Edwards B., Juo R.R., Voyta J.C., Tisdale M., and Bethell R.C. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280 (2000) 291-300
8. Castrucci M.R., Donatelli I., Sidoli L., Barigazzi G., Kawaoka Y., and Webster R.G. Genetic reassortment between avian and human influenza A viruses in Italian pigs. Virology 193 (1993) 503-506
9. Claas E.C., Kawaoka Y., de Jong J.C., Masurel N., and Webster R.G. Infection of children with avian-human reassortant influenza virus from pigs in Europe. Virology 204 (1994) 453-457
10. de Jong J.C., van Nieuwstadt A.P., Kimman T.G., Loeffen W.L., Bestebroer T.M., Bijlsma K., Verweij C., Osterhaus A.D., and Class E.C. Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy. Vaccine 17 (1999) 1321-1328
11. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., and Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672
12. Ferraris O., Kessler N., and Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 68 (2005) 43-48
13. Fouchier R.A., Munster V., Wallensten A., Bestebroer T.M., Herfst S., Smith D., Rimmelzwaan G.F., Olsen B., and Osterhaus A.D. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79 (2005) 2814-2822
14. Govorkova E.A., Leneva I.A., Goloubeva O.G., Bush K., and Webster R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45 (2001) 2723-2732
15. Gregory V., Lim W., Cameron K., Bennett M., Marozin S., Klimov A., Hall H., Cox N., Hay A., and Lin Y.P. Infection of a child in Hong Kong by an influenza A H3N2 virus closely related to viruses circulating in European pigs. J. Gen. Virol. 82 (2001) 1397-1406
16. Gubareva L.V., Bethell R., Hart G.J., Murti K.G., Penn C.R., and Webster R.G. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70 (1996) 1818-1827
17. Gubareva L.V., Kaiser L., and Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 355 (2000) 827-835
18. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., and Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183 (2001) 523-531
19. Hayden F., Klimov A., Tashiro M., Hay A., Monto A., McKimm-Breschkin J., Macken C., Hampson A., Webster R.G., Amyard M., and Zambon M. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antiviral Ther. 10 (2005) 873-877
20. Hayden F.G., and Hay A.J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176 (1992) 119-130
21. Ilyushina N.A., Govorkova E.A., and Webster R.G. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 341 (2005) 102-106
22. Ito T., Couceiro J.N., Kelm S., Baum L.G., Krauss S., Castrucci M.R., Donatelli I., Kida H., Paulson J.C., Webster R.G., and Kawaoka Y. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J. Virol. 72 (1998) 7367-7373
23. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
24. Matrosovich M., Matrosovich T., Carr J., Roberts N.A., and Klenk H.D. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77 (2003) 8418-8425
25. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 (2003) 2264-2272
26. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 47 (2000) 1-17
27. McKimm-Breschkin J.L., Blick T.J., Sahasrabudhe A., Tiong T., Marshall D., Hart G.J., Bethell R.C., and Penn C.R. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40 (1996) 40-46
28. McKimm-Breschkin J.L., Sahasrabudhe A., Blick T.J., McDonald M., Colman P.M., Hart G.J., Bethell R.C., and Varghese J.N. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 72 (1998) 2456-2462
29. Mishin V.P., Novikov D., Hayden F.G., and Gubareva L.V. Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J. Virol. 79 (2005) 12416-12424
30. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 (2005) 1363-1373
31. Nobusawa E., Aoyama T., Kato H., Suzuki Y., Tateno Y., and Nakajima K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182 (1991) 475-485
32. Paget, W.J., Meijer, A., Falcao, J.M., de Jong, J.C., Kyncl, J., Meerhoff, T.J., Meuwissen, L.E., Nicoll, A., van der Velden, J., 2006. Seasonal influenza activity for 2005-2006 season seems to be ending in most European countries. Euro Surveill, 11, E060413.2.
33. Puthavathana P., Auewarakul P., Charoenying P.C., Sangsiriwut K., Pooruk P., Boonnak K., Khanyok R., Thawachsupa P., Kijphati R., and Sawanpanyalert P. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J. Gen. Virol. 86 (2005) 423-433
34. Schmidtke M., Zell R., Bauer K., Krumbholz A., Schrader C., Suess J., and Wutzler P. Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 49 (2006) 286-293
35. Schrader C., and Suess J. Genetic characterization of a porcine H1N2 influenza virus strain isolated in Germany. Intervirology 46 (2003) 66-70
36. Schrader C., and Suess J. Molecular epidemiology of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 2001. Intervirology 47 (2004) 72-77
37. Shiraishi K., Mitamura K., Sakai-Tagawa Y., Goto H., Sugaya N., and Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J. Infect. Dis. 188 (2003) 57-61
38. Staschke K.A., Colacino J.M., Baxter A.J., Air G.M., Bansal A., Hornback W.J., Munroe J.E., and Laver W.G. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214 (1995) 642-646
39. Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10 (2000) 45-55
40. Wagner R., Matrosovich M., and Klenk H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12 (2002) 159-166
41. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., and Hayden F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41 (2003) 742-750
42. Wutzler P., Kossow K.D., Lode H., Ruf B.R., Scholz H., and Vogel G.E. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J. Clin. Virol. 31 (2004) 84-91
43. Yuen K.Y., and Wong S.S. Human infection by avian influenza A H5N1. Hong Kong Med. J. 11 (2005) 189-199